Compare · ITOC vs MDT
ITOC vs MDT
Side-by-side comparison of iTonic Holdings Ltd (ITOC) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ITOC and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT carries a market cap of $138.66B.
- Over the past year, ITOC is down 99.2% and MDT is down 0.8% - MDT leads by 98.4 points.
- MDT has been more active in the news (6 items in the past 4 weeks vs 3 for ITOC).
- MDT has more recent analyst coverage (25 ratings vs 0 for ITOC).
- Company
- iTonic Holdings Ltd
- Medtronic plc.
- Price
- $0.38+31.89%
- $83.32-0.55%
- Market cap
- -
- $138.66B
- 1M return
- -94.10%
- -5.21%
- 1Y return
- -99.22%
- -0.81%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 3
- 6
- Recent ratings
- 0
- 25
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest ITOC
- SEC Form 6-K filed by iTonic Holdings Ltd
- iTonic Holdings Ltd Granted An Extension of Additional 180-Day by Nasdaq to Regain Compliance with Minimum Bid Price Rule
- SEC Form 3 filed by new insider Zhang Jianfei
- Amendment: SEC Form 20-F/A filed by iTonic Holdings Ltd
- SEC Form 20-F filed by iTonic Holdings Ltd
- SEC Form 6-K filed by iTonic Holdings Ltd
- SEC Form 3 filed by new insider Zhang Pengfei
- SEC Form 3 filed by new insider Li Zhixin
- SEC Form EFFECT filed by iTonic Holdings Ltd
- SEC Form 6-K filed by iTonic Holdings Ltd
Latest MDT
- Medtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continues
- Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
- Medtronic completes acquisition of CathWorks, expanding its leadership in transforming care for patients with cardiovascular disease
- The Infrastructure Play Hiding in Plain Sight Across Cardiac Care
- Medtronic to announce financial results for its fourth quarter and full fiscal year 2026
- Telix Strengthens Board with Additional Director Appointments
- Amendment: SEC Form SCHEDULE 13G/A filed by Medtronic plc.
- Medtronic Receives FDA Clearance for Stealth AXiS™ Surgical System for Cranial and ENT Procedures
- Medtronic plc. filed SEC Form 8-K: Regulation FD Disclosure
- Medtronic OmniaSecure™ defibrillation lead is the first lead of its kind to receive FDA approval for conduction system pacing